NDLI: Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Please wait, while we are loading the content...

Year: 2017 Volume: 49

Year: 2016 Volume: 48

Year: 2015 Volume: 47

Year: 2014 Volume: 46

Year: 2013 Volume: 45

Year: 2012 Volume: 44

Year: 2011 Volume: 43

Year: 2010 Volume: 42

Year: 2010 Volume: 42 Issue: 10

Year: 2010 Volume: 42 Issue: 9

Year: 2010 Volume: 42 Issue: 9 Supplementary

Year: 2010 Volume: 42 Issue: 8

Spain's National Health System. Preface.

Results of a living donor kidney promotion program.

One-year follow-up of en bloc renal transplants from pediatric donors in adult recipients.

Renal transplantation in old recipients from expanded criteria donors selected by kidney biopsy.

Treatment of acute antibody-mediated rejection: a single-center experience.

Does the difference in donor and recipient weight influence renal graft survival?

Influence of interleukin-6 promoter polymorphism -174 g/c on kidney graft outcome.

Influence of early graft function after renal transplantation and its impact on long-term graft and patient survival.

Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.

Quantitative assessment of serum free light chains in renal transplantation.

Toward personalized medicine in renal transplantation.

Ambulatory blood pressure monitoring in renal transplant patients: should it be routinely performed?

Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy.

De novo anti-HLA antibodies in renal allograft recipients: a cross-section study.

Kidney transplant recipients show an increase in the ratio of T-cell effector memory/central memory as compared to nontransplant recipients on the waiting list.

Creatinine clearance and proteinuria as early markers of kidney graft survival.

Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.

Analysis of urinary gene expression of epithelial-mesenchymal transition markers in kidney transplant recipients.

Does JC polyomavirus cause nephropathy in renal transplant patients?

Deflux injections for vesicoureteral reflux in transplanted kidneys.

Posttransplant inflammation associated with onset of chronic kidney disease.

Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.

Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus.

Inflammation, metalloproteinases, and growth factors in the development of carotid atherosclerosis in renal transplant patients.

Risk of cardiovascular disease associated with refractory hypertension in renal transplant recipients.

Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.

Elevated serum gamma-glutamyltransferase and hypomagnesemia are not related with new-onset diabetes after transplantation.

Vitamin D deficiency in a renal transplant population: safe repletion with moderate doses of calcidiol.

Cholecalciferol supplements improve vitamin D deficiency in renal transplant recipients.

Effect of paricalcitol on the urinary peptidome of kidney transplant patients.

Vascular thrombosis after kidney transplantation: predisposing factors and risk index.

Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (mircera): the Anemiatrans Group.

Erythropoietin resistance as surrogate marker of graft and patient survival in renal transplantation: 3-year prospective multicenter study.

Epidemiology of pneumonia in kidney transplantation.

Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance.

Candiduria in renal transplant recipients: incidence, clinical repercussion, and treatment indication.

Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+/R-) kidney transplant recipients: a single-center experience.

Exploring mass spectrometry suitability to examine human liver graft metabonomic profiles.

New alternatives to the treatment of acute liver failure.

Comparison of anxious and depressive symptomatology among pretransplant hepatic patients and their relatives.

Influence of relatives' anxious symptomatology on the quality of life of pretransplant hepatic patients.

Covered metal stents for the treatment of biliary complications after orthotopic liver transplantation.

Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis.

Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood.

Use of fully covered self-expandable stent in biliary complications after liver transplantation: a case series.

Cardiovascular events after simultaneous pancreas-kidney transplantation.

Prevalence of donor-transmitted coronary artery disease and its influence on heart transplant outcomes.

Proliferation signal inhibitors in heart transplantation: a 5-year experience.

Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase.

Temporal trends in the use of proliferation signal inhibitors in maintenance heart transplantation: a Spanish multicenter study.

Incidence and risk factors for nonmelanoma skin cancer after heart transplantation.

Long-term outcome in heart transplant patients with pretransplant malignancies.

The prognosis of noncutaneous, nonlymphomatous malignancy after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.

Efficacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after heart transplantation.

Timing, etiology, and location of first infection in first year after heart transplantation.

Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant.

Lung transplantation for bronchiolitis obliterans after allogenic bone marrow transplantation.

Influence of body mass index in the postoperative evolution after lung transplantation.

Genetic polymorphisms and individualized tacrolimus dosing.

Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience.

Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.

Mycophenolate acid vs mycophenolate mofetil therapy.

Evaluation of a fully automated method for the determination of sirolimus.

Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.

Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.

Mycobacterium abscessus infection in transplant recipients.

Inter-alpha-trypsin inhibitor heavy chain 4 as a marker of acute rejection in pancreas allotransplantation in pigs.

Relevance of epidermal growth factor to improve steatotic liver preservation in IGL-1 solution.

Portal revascularization in the setting of cavernous transformation through a paracholedocal vein: a case report.

Severe rhabdomyolysis after allogeneic transplantation of facial structures: a case report.

The 6th Congress of The Andalusian Society of Organ and Tissue Transplantation (SATOT).

Can we accept donors who have suffered a resuscitated cardiac arrest?

International multicenter opinion study: administrative personnel from Spanish and Mexican health centers faced with human organ donation for transplantation.

Attitudes toward islet cell and tissue xenotransplantation among kidney and liver patients on the transplant waiting list.

Attitude toward living liver donation in transplant hospitals in Spain, Mexico and Cuba.

Evaluation of attitudes toward living organ donation: a multicenter study of compulsory secondary school education teachers.

Evaluation of the law of presumed consent after brain death by Spanish journalism students.

From where do our children receive information about organ donation and transplantation?

Welsh citizens in south-eastern Spain: a study of attitude toward organ donation.

Transthoracic echocardiographic findings in patients with chronic kidney disease awaiting kidney transplantation.

Prevalence of cardiovascular disease in kidney transplant candidates: outpatient cardiac evaluation.

Results of living kidney donation in Andalusia: 2006-2009.

Renal Transplant Register of Andalusia, 2010 Report: survival in relation to the factors used in recipient selection.

Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.

Recovery of native renal function after kidney transplantation.

Cases of swine flu in kidney transplant recipients in our hospital.

Urologic complications after kidney transplantation: involvement of the double-J stent and the urologic suture.

Coping styles of patients on the liver transplant waiting list.

Obsessive-compulsive psychological symptoms of patients on the liver transplant waiting list.

Outcomes of liver transplantation in candidates with portal vein thrombosis.

Variability of the extrahepatic arterial anatomy in 500 hepatic grafts.

Thirteen cases of liver-kidney transplantation.

Intraoperative pH values after N-acetylcysteine administration during liver transplantation.

Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.

Posttransplantation portal thrombosis secondary to splenorenal shunt persistence.

Survival after cardiac transplantation: influence of the previous cardiopathy in the recipient.

Cardiac allograft vasculopathy: coronary computed tomography and virtual histology assessment.

Impact of overweight on survival and primary graft failure after heart transplantation.

Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation.

Clinical predictors of immunotolerance in heart transplantation.

Normalization of the heart rate response to exercise 6 months after cardiac transplantation.

Adiponectin and graft vascular disease after cardiac transplantation.

Safety and effectiveness of ivabradine after cardiac transplantation.

Kidney failure after heart transplantation.

Mortality from renal dysfunction in heart transplant patients: creatinine versus glomerular filtration rate.

Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation.

Post-heart transplant tumors: chronology and impact on survival.

Considerations regarding major bleeding after cardiac transplantation.

Lymphomas in heart transplant recipients: do antivirals protect against the neoplastic effect of anti-CD3 monoclonal antibody?

Bone mineral density in lung transplant candidates.

Results of lung transplantation in idiopathic pulmonary fibrosis patients.

Experience of the Reina Sofia hospital in lobar lung transplantation.

Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment.

Complications during clinical evolution in lung transplantation: pulmonary embolism.

Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies.

Clinical utility of real-time polymerase chain reaction to quantify cytomegalovirus replication in allogeneic stem cell transplant recipients with different prevention strategies.

Differences in cytomegalovirus replication quantified using quantitative polymerase chain reaction and antigenemia after allogeneic stem cell transplantation.

Design of a real-time quantitative polymerase chain reaction to assess human complement regulatory protein gene expression in polytransgenic xenograft pigs.

Validation of xCELLigence real-time cell analyzer to assess compatibility in xenotransplantation with pig-to-baboon model.

Effects of deep hypothermic preservation on posttransplant viability of tracheal grafts.

New technologies developed in the 1960s, especially in the fields of immunogenetics and cell biology, inaugurated the era of organ transplantation. Preface.

European marrow donor information system: concept and praxis.

Collaboration between hematopoietic stem cell donor registry and cord blood banks.

Human leukocyte antigen proficiency testing for Central and Eastern Europe: a summary of over 10 years of activity.

Association of HLA haplotypes with paroxysmal nocturnal hemoglobinuria.

Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.

Interleukin-17-producing cells increase among CD4+ lymphocytes before overt manifestation of acute graft-versus-host disease.

CXCL12 gene polymorphism and hematologic recovery after transplantation of peripheral blood progenitor cells.

Gene-modified cellular vaccines: technologic aspects and clinical problems.

Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.

The impact of H-Y mismatches on results of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.

Phenotype of dendritic cells generated from peripheral blood monocytes of patients with ovarian cancer.

Dendritic-cell tumor vaccines.

Wilms' tumor 1 as a novel target for immunotherapy of leukemia.

Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association.

Activity of the National Polish Bone Marrow Donor Registry--analysis of the matching process successfully completed with hematopoietic stem cell transplantation.

Hand transplantation--Polish program.

Preclinical and clinical studies on application of human myoblasts in regeneration of the postinfarction heart.

Role of glucocorticoid-induced leucine zipper (GILZ) expression by dendritic cells in tolerance induction.

'Medical writing' and ghostwriting as ethical challenges in medical communication.

Year: 2010 Volume: 42 Issue: 7

Year: 2010 Volume: 42 Issue: 6

Year: 2010 Volume: 42 Issue: 5

Year: 2010 Volume: 42 Issue: 4

Year: 2010 Volume: 42 Issue: 3

Year: 2010 Volume: 42 Issue: 2

Year: 2010 Volume: 42 Issue: 1

Year: 2009 Volume: 41

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Sánchez-Fructuoso, A. I. Ruiz, J. C. Pérez-Flores, I. Gómez Alamillo, C. Calvo Romero, N. Arias, M.
Description	Country affiliation: Spain Author Affiliation: Sánchez-Fructuoso AI ( Department of Nephrology, Hospital Clínico San Carlos, Madrid, Spain. sanchezfruct@telefonica.net)
Abstract	BACKGROUND: Inhibitors of mammalian target of rapamycin (mTORi) have been suggested as an alternative to calcineurin inhibitors (CNIs) to treat stable renal transplant recipients. However, their use has been significantly limited owing to a high incidence of side effects. OBJECTIVE: To compare the rate of dropout (mTORi elimination and CNI reintroduction) caused by side effects among renal transplant patients converted to everolimus (EVL) or sirolimus (SRL). METHODS: Between October 1999 and February 2010, 409 subjects were converted to an mTORi at least 3 months after transplantation, including 220 (53.8%) to EVL and 189 (46.2%) to SRL. Most patients were under CNI therapy. Patients were followed for a median of 35 months (interquartile range [IQR], 18-50 months). RESULTS: mTORi treatment was prematurely eliminated due to adverse events in 112 patients. The median time between the initiation of mTORi and discontinuation was 5.7 months (IQR, 1.9-15.7 months; range, 0.2-48 months): 5.5 (IQR, 1.6-16.3) in the EVL group and 7.4 (IQR, 2.6-15.6) in the SRL group. In the EVL group, the drug was stopped in 69 patients (31.4%), and in the SRL group in 43 patients (22.8%; P=.051). The most important causes of discontinuation were severe infections (2.3% in EVL group and 4.8% in SRL group; P=.17), pneumonitis (6.8 % in EVL group and 4.8 in SRL group; P=.38), acute rejection episode (4.1% in EVL group and 1.6% in SRL group; P=.13), proteinuria (4.1% in EVL group and 1.6% in SRL group; P=.13), renal function deterioration (2.3% in EVL group and 2.1% in SRL group; P=.91), and severe dermal eruption (2.3% in EVL group and 0.5% in SRL group; P=.14). CONCLUSIONS: Although the overall incidence discontinuations due to side effects was higher in the EVL group, there was no greater frequency of severe side effects, such as pneumonitis, proteinuria, acute rejection episodes, renal function deterioration, or dermal eruptions.
File Format	HTM / HTML
ISSN	00411345
Issue Number	8
Volume Number	42
e-ISSN	18732623
Journal	Transplantation Proceedings
Language	English
Publisher	Elsevier
Publisher Date	2010-10-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Transplantation__semicolon__medicine Immunosuppressive Agents Adverse Effects Kidney Transplantation Sirolimus Analogs & Derivatives Tor Serine-threonine Kinases Antagonists & Inhibitors Everolimus Humans Therapeutic Use Comparative Study Journal Article
Content Type	Text
Resource Type	Article
Subject	Transplantation Surgery

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in